Clinical Trial Update: Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a completed Phase 1/2 trial evaluating autologous Melan-A/MART-1–specific cytotoxic T lymphocytes for metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous Melan-A/MART-1-specific CTL clones (Melan-A/MART-1-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Nantes University Hospital | Conditions: Immunotherapy | Phase 1, Phase 2 | Status: COMPLETED